RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis.
Human umbilical cord mesenchymal stem cell-derived exosomes carrying miR-1827 downregulate SUCNR1 to inhibit macrophage M2 polarization and prevent colorectal liver metastasis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
microRNA-1827(miR-1827)被认为富集于间充质干细胞来源的外泌体(MSCs-Exos)中。近期一项研究已探讨了人脐带间充质干细胞来源的外泌体(hUC-MSCs-Exos)对结直肠癌(CRC)转移的抑制作用。
因此,本研究旨在探究hUC-MSCs-Exos是否可通过介导miR-1827调控CRC的肝转移。采用透射电子显微镜(TEM)和纳米颗粒跟踪分析(NTA)对hUC-MSCs-Exos进行鉴定。利用功能获得和功能缺失方法,改变miR-1827和琥珀酸受体1(SUCNR1)的表达。随后,通过CCK-8和Transwell实验评估CRC细胞的生物学功能,并通过流式细胞术检测巨噬细胞M2极化。应用双荧光素酶报告基因实验阐明miR-1827与SUCNR1之间的相互作用。将CRC细胞与hUC-MSCs-Exos共孵育,并向荷瘤小鼠注射hUC-MSCs-Exos,以检测其对CRC细胞生长和转移的影响。SUCNR1在CRC中低表达,可促进CRC细胞生长和巨噬细胞M2极化。miR-1827可靶向SUCNR1,从而抑制CRC的进展和转移。hUC-MSCs-Exos携带miR-1827,通过下调SUCNR1表达抑制M2巨噬细胞极化,并抑制CRC细胞的增殖、迁移和侵袭特性。
此外,携带miR-1827的hUC-MSCs-Exos在体内阻断了CRC肝转移。这些发现表明,hUC-MSCs-Exos通过诱导miR-1827靶向抑制SUCNR1,成为CRC中M2巨噬细胞极化和肝转移的抑制剂。这为理解基于Exos的CRC靶向治疗的机制提供了理论基础。
microRNA-1827 (miR-1827) is proposed to be enriched in exosomes from mesenchymal stem cells (MSCs-Exos). A recent study has addressed the suppressive effect of exosomes from human umbilical cord mesenchymal stem cells (hUC-MSCs-Exos) on colorectal cancer (CRC) metastasis. Hence, our study aims at investigating whether hUC-MSCs-Exos can modulate the liver metastasis in CRC by mediating miR-1827. Transmission electron microscopy (TEM) and nanoparticle tracking analysis (NTA) were used to identify hUC-MSCs-Exos. Using gain- and loss-of-function approaches, the expression of miR-1827 and succinate receptor 1 (SUCNR1) was altered.
Consequently, the biological functions of CRC cells were assessed by CCK-8 and Transwell assays and macrophage M2 polarization was assayed by flow cytometry. Dual-luciferase reporter assay was applied to clarify interaction between miR-1827 and SUCNR1. CRC cells were incubated with hUC-MSCs-Exos and tumor-bearing mice were injected with hUC-MSCs-Exos to examine the effects on CRC cell growth and metastasis.
SUCNR1, lowly expressed in CRC, could promote CRC cell growth and macrophage M2 polarization. miR-1827 could target SUCNR1 and hence suppress the progression and metastasis of CRC. hUC-MSCs-Exos carried miR-1827 to inhibit M2 macrophage polarization by downregulating SUCNR1 expression, and inhibited proliferating, migrating and invading properties of CRC cells.
Furthermore, hUC-MSCs-Exos carrying miR-1827 blocked CRC liver metastasis in vivo.
These findings indicate hUC-MSCs-Exos as an inhibitor of M2 macrophage polarization and liver metastasis in CRC through inducing miR-1827-targeted inhibition of SUCNR1. This provides a theoretical basis for understanding the mechanisms underlying Exos-based target therapy for CRC.
MEMBER ACCOUNT
登录成功会直接打开下一页。